[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335232-105":59,"doc-detail-335232-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","microrna-profiling-in-papillary-thyroid-cancer","MicroRNA Profiling in Papillary Thyroid Cancer","","Genetic alterations drive the pathogenesis and prognosis of papillary thyroid carcinoma (PTC), and miRNA dysregulation has been implicated in cancer development. This study performs original molecular diagnostics on patient-related tissue samples to identify dysregulated miRNAs associated with PTC by sequencing larger, control-matched cohorts and surveying a broader range of miRNA types. Expression of 2656 human miRNAs was assessed across 236 thyroid tissue samples (118 tumor/control pairs). KEGG pathway enrichment and GO analyses linked altered miRNAs to biological processes, signaling pathways, molecular functions, and cellular components. Thirty significant differential miRNAs with at least ±1 log2 fold change were detected, including upregulated miR-551b, miR-146b, miR-221, miR-222, and miR-375, and downregulated miR-873 and miR-204. Additional database pattern similarities and 352 associations with clinicopathological variables support a distinct miRNA expression profile with potential biomarker and therapeutic target value for PTC diagnosis, prognosis, and future treatment strategies.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/microrna-profiling-in-papillary-thyroid-cancer/335232/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/microrna-profiling-in-papillary-thyroid-cancer/335232.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the main goal of the study on papillary thyroid carcinoma?","Question",{"text":113,"@type":114},"To identify dysregulated miRNAs associated with PTC by analyzing a large number of control-matched tumor tissue samples and a wider variety of miRNA types.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How many thyroid tissue samples and miRNAs were analyzed?",{"text":118,"@type":114},"The study analyzed 236 thyroid tissue samples (118 tumor/control pairs) and measured expression levels of 2656 different human miRNAs.",{"name":120,"@type":111,"acceptedAnswer":121},"What analytical approaches were used to connect miRNA dysregulation to biology in PTC?",{"text":122,"@type":114},"KEGG pathway enrichment and GO framework analysis were used to link altered miRNAs to biological processes, signaling pathways, molecular functions, and cellular components.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},335232,1790186821,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":4},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Article  \nMicroRNA Profiling in Papillary Thyroid Cancer  \nRichard Armos 1,2, Bence Bojtor 1, Marton Papp 3, Ildiko Illyes 4, Balazs Lengyel 1, Andras Kiss 1, Balazs Szili 1, Balint Tobias 1,2, Bernadett Balla 2, Henriett Piko 1, Anett Illes 1, Zsuzsanna Putz 1,2, Andras Kiss 4,  \nErika Toth 5, Istvan Takacs 1, Janos P. Kosa 1,2,† and Peter Lakatos 1,2, *,†  \nCitation: Armos, R.; Bojtor, B.; Papp, M.; Illyes, I.; Lengyel, B.; Kiss, A.; Szili, B.; Tobias, B.; Balla, B.; Piko, H.; et al. MicroRNA Profiling in Papillary Thyroid Cancer. Int. J. Mol. Sci. 2024, 25, 9362. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms25179362  \nAcademic Editor: Malgorzata Gabriela Wasniewska  \nReceived: 3 July 2024  \nRevised: 23 August 2024  \nAccepted: 28 August 2024  \nPublished: 29 August 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Medicine and Oncology, Faculty of Medicine, Semmelweis University, 1083 Budapest,  \nHungary; [armos.richard@semmelweis.hu](armos.richard@semmelweis.hu) (R.A.); [bojtorbence01@gmail.com](bojtorbence01@gmail.com) (B.B.);  \n[lengyel.balazs.levente@semmelweis.hu](lengyel.balazs.levente@semmelweis.hu) (B.L.); [kiss.andras1@semmelweis.hu](kiss.andras1@semmelweis.hu) (A.K.);  \n[szili.balazs@semmelweis.hu](szili.balazs@semmelweis.hu) (B.S.); [tobias.balint@gmail.com](tobias.balint@gmail.com) (B.T.); [piko.henriett@semmelweis.hu](piko.henriett@semmelweis.hu) (H.P.);  \n[barkaszine.dr.illes.anett@semmelweis.hu](barkaszine.dr.illes.anett@semmelweis.hu) (A.I.); [putz.zsuzsanna@med.semmelweis-univ.hu](putz.zsuzsanna@med.semmelweis-univ.hu) (Z.P.);  \n[takacs.istvan@semmelweis.hu](takacs.istvan@semmelweis.hu) (I.T.); [kosa.janos@semmelweis.hu](kosa.janos@semmelweis.hu) (J.P.K.)  \n2 SE HUN-REN-TKI ENDOMOLPAT Research Group, 1085 Budapest, Hungary; [balladetti@gmail.com](balladetti@gmail.com)  \n3 Centre for Bioinformatics, University of Veterinary Medicine, 1078 Budapest, Hungary; [pappmarci95@gmail.com](pappmarci95@gmail.com)  \n4 Department of Pathology, Forensic and Insurance Medicine, Faculty of Medicine, Semmelweis University, 1091 Budapest, Hungary; [illyes.ildiko@semmelweis.hu](illyes.ildiko@semmelweis.hu) (I.I.); [kiss.andras@semmelweis.hu](kiss.andras@semmelweis.hu) (A.K.)  \n5 Department of Surgical and Molecular Pathology, National Institute of Oncology, 1122 Budapest, Hungary; [dr.toth.erika@oncol.hu](dr.toth.erika@oncol.hu)  \n* Correspondence: [lakatos.peter@semmelweis.hu](lakatos.peter@semmelweis.hu); Tel.: +36-20-825-8692 † These authors contributed equally to this work.  \nAbstract: Genetic alterations are well known to be related to the pathogenesis and prognosis of papillary thyroid carcinoma (PTC) . Some miRNA expression dysregulations have previously been described in the context of cancer development including thyroid carcinoma. In our study, we performed original molecular diagnostics on tissue samples related to our own patients. We aimed to identify all dysregulated miRNAs in potential association with PTC development via sequencing much higher numbers of control-matched PTC tissue samples and analyzing a wider variety of miRNA types than previous studies. We analyzed the expression levels of 2656 different human miRNAs in the context of 236 thyroid tissue samples (118 tumor and control pairs) related to anonymized PTC cases. Also, KEGG pathway enrichment analysis and GO framework analysis were used to establish the links between miRNA dysregulation and certain biological processes, pathways of signaling, molecular functions, and cellular components. A total of 30 significant differential miRNA expressions with at least ±1 log2 fold change were fo","cbCaiaiNyfJD2j09","https://ap.wps.com/l/cbCaiaiNyfJD2j09","pdf",8418013,21,"English","# Introduction\n## Study focus on miRNAs in PTC\n## Methods overview: sequencing and differential expression\n## Bioinformatic enrichment: KEGG and GO analyses\n## Results: differential miRNA list and fold changes\n## Clinical associations and biomarker potential","[{\"question\":\"What was the main goal of the study on papillary thyroid carcinoma?\",\"answer\":\"To identify dysregulated miRNAs associated with PTC by analyzing a large number of control-matched tumor tissue samples and a wider variety of miRNA types.\"},{\"question\":\"How many thyroid tissue samples and miRNAs were analyzed?\",\"answer\":\"The study analyzed 236 thyroid tissue samples (118 tumor/control pairs) and measured expression levels of 2656 different human miRNAs.\"},{\"question\":\"What analytical approaches were used to connect miRNA dysregulation to biology in PTC?\",\"answer\":\"KEGG pathway enrichment and GO framework analysis were used to link altered miRNAs to biological processes, signaling pathways, molecular functions, and cellular components.\"}]","MicroRNA Profiling in Papillary Thyroid Cancer | PDF",1790010253,53]